GUARDANT HEALTH INC (GH) Stock News
NASDAQ:GH - Nasdaq - US40131M1099 - Common Stock - Currency: USD
GH Latest News, Press Relases and Analysis
Guardant Health to Participate in Upcoming Investor Conferences
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of 19.67% and 6.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CTMX
Guardant Health’s (NASDAQ:GH) Q1: Strong Sales, Stock Soars
Diagnostics company Guardant Health (NASDAQ:GH) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 20.8% year on year to $203.5 million. The company’s full-year revenue guidance of $885 million at the midpoint came in 3.2% above analysts’ estimates. Its non-GAAP loss of $0.49 per share was 17% above analysts’ consensus estimates.
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
Guardant Health (GH) Q1 Earnings Report Preview: What To Look For
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting earnings tomorrow after market hours. Here’s what you need to know.
Amgen (AMGN) Earnings Expected to Grow: Should You Buy?
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: AMGN
Is ConocoPhillips (COP) the Most Undervalued Growth Stock to Buy Now?
We recently published a list of 10 Most Undervalued Growth Stocks to Buy Now. In this article, we are going to take a look at where ConocoPhillips (NYSE:COP) stands against other most undervalued growth stocks to buy now. Growth stocks are companies that grow their revenues and earnings at a faster rate than the overall […]
Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: RGEN
Guardant Health (GH) Rose Following Several Positive News Reports
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index fell 4.27% in the first quarter of 2025, marking a sluggish start to the year for the U.S. equities market. On the other hand, bonds […]
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Mettler-Toledo price target lowered to $1,250 from $1,500 at BofA
BofA analyst Michael Ryskin lowered the firm’s price target on Mettler-Toledo (MTD) to $1,250 from $1,500 and keeps a Neutral rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especial
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
4 Healthcare Stocks With Massive Gains—and More to Come
Healthcare is the top industry of 2025 so far. These healthcare companies have seen 30% increases in share prices since the beginning of the year.
